Wellington Management Group LLP Has $451 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Wellington Management Group LLP reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 34.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 3,239,021 shares of the life sciences company’s stock after selling 1,726,115 shares during the quarter. Wellington Management Group LLP owned approximately 2.04% of Illumina worth $451,001,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. STF Management LP lifted its stake in Illumina by 3.5% in the fourth quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock valued at $368,000 after buying an additional 90 shares during the period. Clear Creek Financial Management LLC raised its position in shares of Illumina by 6.3% during the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock worth $236,000 after purchasing an additional 100 shares during the period. Lido Advisors LLC raised its position in shares of Illumina by 6.1% during the third quarter. Lido Advisors LLC now owns 1,859 shares of the life sciences company’s stock worth $255,000 after purchasing an additional 107 shares during the period. Quent Capital LLC raised its position in shares of Illumina by 45.2% during the fourth quarter. Quent Capital LLC now owns 363 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 113 shares during the period. Finally, ICICI Prudential Asset Management Co Ltd raised its position in shares of Illumina by 9.4% during the fourth quarter. ICICI Prudential Asset Management Co Ltd now owns 1,541 shares of the life sciences company’s stock worth $215,000 after purchasing an additional 133 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Down 0.5 %

ILMN stock opened at $108.66 on Monday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $17.31 billion, a PE ratio of -13.33 and a beta of 1.20. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $212.49. The business’s 50 day simple moving average is $114.93 and its 200 day simple moving average is $127.78.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm’s revenue was down 1.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.08 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 1.04 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Evercore ISI dropped their price target on Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 11th. Jefferies Financial Group assumed coverage on Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 price target on the stock. StockNews.com began coverage on Illumina in a research report on Friday. They set a “buy” rating on the stock. OTR Global reissued a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Finally, Scotiabank dropped their target price on Illumina from $185.00 to $176.00 and set a “sector outperform” rating on the stock in a research report on Monday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $158.14.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.